Celtaxsys commences acebilustat phase 2 trial in individuals with cystic fibrosis in US Celtaxsys, a clinical stage medication development company centered on advancing care for patients experiencing orphan inflammatory illnesses, announced today the commencement of the US arm of an international stage 2 clinical trial for its flagship compound, acebilustat, in individuals with cystic fibrosis . The study will be carried out at 60 sites in the United States and European Union approximately, with the EU sites expected to begin enrollment early 2016. This landmark medical trial examining once-daily oral acebilustat treatment over 48 weeks may be the first to determine proof-of-concept for an anti-inflammatory treatment particularly designed to prevent long-term lack of lung function in CF patients Levitra-varje-dag.html .
As the advent of important new treatments, including CFTR modulators, is a true game-changer for many CF patients, lung swelling continues to be a primary cause of CF individual mortality and morbidity,’ stated Greg Duncan, Celtaxsys CEO. ‘Once-daily oral acebilustat treatment can potentially address the underlying swelling that results in irreversible lung function decline and takes place in all CF individuals, independent of CFTR genotype.’ Related StoriesMyriad RBM's DiscoveryMAP system identifies protein biomarkers linked to CV events in diabetes patientsDiscovery could offer clues to how some infections control expression of genetic materialUnique, tiny proteins cage developed to provide chemotherapy chemicals to tumor cellsAdded Sanjeev Ahuja directly, MD and Chief Medical Officer at Celtaxsys, ‘The interplay between illness and inflammation may be the main driver for lung function decline in CF.